Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018

Brendan Flannery, Jessie R Chung, Edward A Belongia, Huong Q McLean, Manjusha Gaglani, Kempapura Murthy, Richard K Zimmerman, Mary Patricia Nowalk, Michael L Jackson, Lisa A Jackson, Arnold S Monto, Emily T Martin, Angie Foust, Wendy Sessions, LaShondra Berman, John R Barnes, Sarah Spencer, Alicia M Fry, Brendan Flannery, Jessie R Chung, Edward A Belongia, Huong Q McLean, Manjusha Gaglani, Kempapura Murthy, Richard K Zimmerman, Mary Patricia Nowalk, Michael L Jackson, Lisa A Jackson, Arnold S Monto, Emily T Martin, Angie Foust, Wendy Sessions, LaShondra Berman, John R Barnes, Sarah Spencer, Alicia M Fry

Abstract

In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months (1). During each influenza season since 2004-05, CDC has estimated the effectiveness of seasonal influenza vaccine to prevent laboratory-confirmed influenza associated with medically attended acute respiratory illness (ARI). This report uses data from 4,562 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during November 2, 2017-February 3, 2018. During this period, overall adjusted vaccine effectiveness (VE) against influenza A and influenza B virus infection associated with medically attended ARI was 36% (95% confidence interval [CI] = 27%-44%). Most (69%) influenza infections were caused by A(H3N2) viruses. VE was estimated to be 25% (CI = 13% to 36%) against illness caused by influenza A(H3N2) virus, 67% (CI = 54%-76%) against A(H1N1)pdm09 viruses, and 42% (CI = 25%-56%) against influenza B viruses. These early VE estimates underscore the need for ongoing influenza prevention and treatment measures. CDC continues to recommend influenza vaccination because the vaccine can still prevent some infections with currently circulating influenza viruses, which are expected to continue circulating for several weeks. Even with current vaccine effectiveness estimates, vaccination will still prevent influenza illness, including thousands of hospitalizations and deaths. Persons aged ≥6 months who have not yet been vaccinated this season should be vaccinated.

Conflict of interest statement

No conflicts of interest were reported.

References

    1. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2017–18 influenza season. MMWR Recomm Rep 2017;66(No. RR-2). 10.15585/mmwr.rr6602a1
    1. Jackson ML, Chung JR, Jackson LA, et al. Influenza vaccine effectiveness in the United States during the 2015–2016 season. N Engl J Med 2017;377:534–43. 10.1056/NEJMoa1700153
    1. Budd AP, Wentworth DE, Blanton L, et al. Update: influenza activity—United States, October 1, 2017–February 3, 2018. MMWR Morb Mortal Wkly Rep 2018;67:169–79.
    1. Skowronski DM, Chambers C, De Serres G, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro Surveill 2018;23. 10.2807/1560-7917.ES.2018.23.5.18-00035
    1. Sullivan SG, Chilver MB, Carville KS, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill 2017;22. 10.2807/1560-7917.ES.2017.22.43.17-00707
    1. Flannery B, Chung JR, Thaker SN, et al. Interim estimates of 2016–17 seasonal influenza vaccine effectiveness—United States, February 2017. MMWR Morb Mortal Wkly Rep 2017;66:167–71. 10.15585/mmwr.mm6606a3
    1. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016;16:942–51. 10.1016/S1473-3099(16)00129-8
    1. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A 2017;114:12578–83. 10.1073/pnas.1712377114
    1. Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog 2017;13:e1006682. 10.1371/journal.ppat.1006682
    1. Fry AM, Kim IK, Reed C, et al. Modeling the effect of different vaccine effectiveness estimates on the number of vaccine-prevented influenza-associated hospitalizations in older adults. Clin Infect Dis 2014;59:406–9. 10.1093/cid/ciu328

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅